Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?
Sam Schulman
Correspondence Thrombosis Service, HHS-General Hospital, 237 Barton Street E, Hamilton, ON L8L 2X2, Canada
Email schulms@mcmaster.ca
This article has no abstract so we have provided the first paragraph of the full text.
The ARTEMIS trial findings presented here by Cohen et al. of the pentasaccharide fondaparinux in a fixed dose of 2.5 mg daily have been published, together with several other large fondaparinux studies. At first glance, all of the trials showed very positive results.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
